nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CYP3A4—Thiotepa—sarcoma	0.107	0.458	CbGbCtD
Solifenacin—CYP3A4—Mitoxantrone—sarcoma	0.0459	0.197	CbGbCtD
Solifenacin—CYP3A4—Vincristine—sarcoma	0.0316	0.136	CbGbCtD
Solifenacin—CYP3A4—Etoposide—sarcoma	0.0289	0.124	CbGbCtD
Solifenacin—CYP3A4—Doxorubicin—sarcoma	0.0197	0.0847	CbGbCtD
Solifenacin—Hepatocellular injury—Epirubicin—sarcoma	0.00331	0.00431	CcSEcCtD
Solifenacin—Infestation NOS—Etoposide—sarcoma	0.0033	0.0043	CcSEcCtD
Solifenacin—Infestation—Etoposide—sarcoma	0.0033	0.0043	CcSEcCtD
Solifenacin—Mediastinal disorder—Vincristine—sarcoma	0.0033	0.0043	CcSEcCtD
Solifenacin—Hyperkalaemia—Epirubicin—sarcoma	0.00325	0.00424	CcSEcCtD
Solifenacin—Renal failure—Etoposide—sarcoma	0.00325	0.00423	CcSEcCtD
Solifenacin—Cystitis noninfective—Epirubicin—sarcoma	0.00323	0.00421	CcSEcCtD
Solifenacin—Mental disorder—Vincristine—sarcoma	0.00321	0.00418	CcSEcCtD
Solifenacin—Cystitis—Epirubicin—sarcoma	0.0032	0.00417	CcSEcCtD
Solifenacin—Cough—Thiotepa—sarcoma	0.00313	0.00409	CcSEcCtD
Solifenacin—Hepatobiliary disease—Etoposide—sarcoma	0.00312	0.00407	CcSEcCtD
Solifenacin—Hypertension—Thiotepa—sarcoma	0.0031	0.00404	CcSEcCtD
Solifenacin—Hepatocellular injury—Doxorubicin—sarcoma	0.00306	0.00399	CcSEcCtD
Solifenacin—Dry eye—Epirubicin—sarcoma	0.00306	0.00398	CcSEcCtD
Solifenacin—Dysgeusia—Mitoxantrone—sarcoma	0.00304	0.00396	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.00304	0.00396	CcSEcCtD
Solifenacin—Hyperkalaemia—Doxorubicin—sarcoma	0.00301	0.00392	CcSEcCtD
Solifenacin—Bladder pain—Epirubicin—sarcoma	0.00299	0.0039	CcSEcCtD
Solifenacin—Cystitis noninfective—Doxorubicin—sarcoma	0.00299	0.0039	CcSEcCtD
Solifenacin—Cystitis—Doxorubicin—sarcoma	0.00296	0.00385	CcSEcCtD
Solifenacin—Confusional state—Thiotepa—sarcoma	0.00296	0.00385	CcSEcCtD
Solifenacin—Urinary tract disorder—Etoposide—sarcoma	0.00293	0.00382	CcSEcCtD
Solifenacin—Vision blurred—Mitoxantrone—sarcoma	0.00292	0.00381	CcSEcCtD
Solifenacin—Infection—Thiotepa—sarcoma	0.00291	0.0038	CcSEcCtD
Solifenacin—Urethral disorder—Etoposide—sarcoma	0.00291	0.00379	CcSEcCtD
Solifenacin—Infection—Dactinomycin—sarcoma	0.00289	0.00377	CcSEcCtD
Solifenacin—Nervous system disorder—Thiotepa—sarcoma	0.00288	0.00375	CcSEcCtD
Solifenacin—Tachycardia—Thiotepa—sarcoma	0.00286	0.00373	CcSEcCtD
Solifenacin—Skin disorder—Thiotepa—sarcoma	0.00285	0.00371	CcSEcCtD
Solifenacin—Dry eye—Doxorubicin—sarcoma	0.00283	0.00369	CcSEcCtD
Solifenacin—Erythema multiforme—Etoposide—sarcoma	0.0028	0.00365	CcSEcCtD
Solifenacin—Eye disorder—Etoposide—sarcoma	0.00277	0.00361	CcSEcCtD
Solifenacin—Bladder pain—Doxorubicin—sarcoma	0.00277	0.00361	CcSEcCtD
Solifenacin—Cardiac disorder—Etoposide—sarcoma	0.00275	0.00359	CcSEcCtD
Solifenacin—Hypertension—Vincristine—sarcoma	0.00275	0.00359	CcSEcCtD
Solifenacin—Cough—Mitoxantrone—sarcoma	0.00271	0.00353	CcSEcCtD
Solifenacin—Angiopathy—Etoposide—sarcoma	0.00269	0.00351	CcSEcCtD
Solifenacin—Hypertension—Mitoxantrone—sarcoma	0.00268	0.00349	CcSEcCtD
Solifenacin—Immune system disorder—Etoposide—sarcoma	0.00268	0.00349	CcSEcCtD
Solifenacin—Mediastinal disorder—Etoposide—sarcoma	0.00267	0.00348	CcSEcCtD
Solifenacin—Somnolence—Thiotepa—sarcoma	0.00261	0.0034	CcSEcCtD
Solifenacin—Anaphylactic shock—Vincristine—sarcoma	0.0026	0.00339	CcSEcCtD
Solifenacin—Infection—Vincristine—sarcoma	0.00258	0.00337	CcSEcCtD
Solifenacin—Dyspepsia—Thiotepa—sarcoma	0.00258	0.00336	CcSEcCtD
Solifenacin—Confusional state—Mitoxantrone—sarcoma	0.00255	0.00333	CcSEcCtD
Solifenacin—Nervous system disorder—Vincristine—sarcoma	0.00255	0.00332	CcSEcCtD
Solifenacin—Decreased appetite—Thiotepa—sarcoma	0.00255	0.00332	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Epirubicin—sarcoma	0.00255	0.00332	CcSEcCtD
Solifenacin—Anaphylactic shock—Mitoxantrone—sarcoma	0.00253	0.0033	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Thiotepa—sarcoma	0.00253	0.0033	CcSEcCtD
Solifenacin—Decreased appetite—Dactinomycin—sarcoma	0.00253	0.0033	CcSEcCtD
Solifenacin—Fatigue—Thiotepa—sarcoma	0.00253	0.0033	CcSEcCtD
Solifenacin—Dysgeusia—Etoposide—sarcoma	0.00253	0.00329	CcSEcCtD
Solifenacin—Renal impairment—Epirubicin—sarcoma	0.00252	0.00329	CcSEcCtD
Solifenacin—Infection—Mitoxantrone—sarcoma	0.00252	0.00328	CcSEcCtD
Solifenacin—Fatigue—Dactinomycin—sarcoma	0.00251	0.00327	CcSEcCtD
Solifenacin—Constipation—Thiotepa—sarcoma	0.00251	0.00327	CcSEcCtD
Solifenacin—Tachycardia—Mitoxantrone—sarcoma	0.00247	0.00322	CcSEcCtD
Solifenacin—Skin disorder—Mitoxantrone—sarcoma	0.00246	0.00321	CcSEcCtD
Solifenacin—Feeling abnormal—Thiotepa—sarcoma	0.00242	0.00315	CcSEcCtD
Solifenacin—Feeling abnormal—Dactinomycin—sarcoma	0.0024	0.00313	CcSEcCtD
Solifenacin—Gastrointestinal pain—Thiotepa—sarcoma	0.0024	0.00313	CcSEcCtD
Solifenacin—Gastrointestinal pain—Dactinomycin—sarcoma	0.00238	0.0031	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Doxorubicin—sarcoma	0.00236	0.00307	CcSEcCtD
Solifenacin—Renal impairment—Doxorubicin—sarcoma	0.00234	0.00304	CcSEcCtD
Solifenacin—Urticaria—Thiotepa—sarcoma	0.00233	0.00304	CcSEcCtD
Solifenacin—Abdominal pain—Thiotepa—sarcoma	0.00232	0.00302	CcSEcCtD
Solifenacin—Abdominal pain—Dactinomycin—sarcoma	0.0023	0.003	CcSEcCtD
Solifenacin—Decreased appetite—Vincristine—sarcoma	0.00226	0.00295	CcSEcCtD
Solifenacin—Cough—Etoposide—sarcoma	0.00225	0.00294	CcSEcCtD
Solifenacin—Somnolence—Mitoxantrone—sarcoma	0.00225	0.00293	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Vincristine—sarcoma	0.00224	0.00293	CcSEcCtD
Solifenacin—Fatigue—Vincristine—sarcoma	0.00224	0.00292	CcSEcCtD
Solifenacin—Dyspepsia—Mitoxantrone—sarcoma	0.00223	0.00291	CcSEcCtD
Solifenacin—Hypertension—Etoposide—sarcoma	0.00223	0.0029	CcSEcCtD
Solifenacin—Constipation—Vincristine—sarcoma	0.00222	0.0029	CcSEcCtD
Solifenacin—Liver function test abnormal—Epirubicin—sarcoma	0.00222	0.00289	CcSEcCtD
Solifenacin—Dry skin—Epirubicin—sarcoma	0.0022	0.00287	CcSEcCtD
Solifenacin—Decreased appetite—Mitoxantrone—sarcoma	0.0022	0.00287	CcSEcCtD
Solifenacin—Abdominal pain upper—Epirubicin—sarcoma	0.00219	0.00286	CcSEcCtD
Solifenacin—Fatigue—Mitoxantrone—sarcoma	0.00218	0.00285	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00218	0.00284	CcSEcCtD
Solifenacin—Constipation—Mitoxantrone—sarcoma	0.00217	0.00282	CcSEcCtD
Solifenacin—Hypersensitivity—Thiotepa—sarcoma	0.00216	0.00282	CcSEcCtD
Solifenacin—Hypersensitivity—Dactinomycin—sarcoma	0.00214	0.00279	CcSEcCtD
Solifenacin—Gastrointestinal pain—Vincristine—sarcoma	0.00213	0.00277	CcSEcCtD
Solifenacin—Confusional state—Etoposide—sarcoma	0.00212	0.00277	CcSEcCtD
Solifenacin—Muscular weakness—Epirubicin—sarcoma	0.00212	0.00276	CcSEcCtD
Solifenacin—Anaphylactic shock—Etoposide—sarcoma	0.00211	0.00275	CcSEcCtD
Solifenacin—Asthenia—Thiotepa—sarcoma	0.0021	0.00274	CcSEcCtD
Solifenacin—Infection—Etoposide—sarcoma	0.00209	0.00273	CcSEcCtD
Solifenacin—Asthenia—Dactinomycin—sarcoma	0.00209	0.00272	CcSEcCtD
Solifenacin—Feeling abnormal—Mitoxantrone—sarcoma	0.00209	0.00272	CcSEcCtD
Solifenacin—Influenza—Epirubicin—sarcoma	0.00208	0.00271	CcSEcCtD
Solifenacin—Pruritus—Thiotepa—sarcoma	0.00207	0.0027	CcSEcCtD
Solifenacin—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00207	0.0027	CcSEcCtD
Solifenacin—Tachycardia—Etoposide—sarcoma	0.00206	0.00268	CcSEcCtD
Solifenacin—Abdominal pain—Vincristine—sarcoma	0.00206	0.00268	CcSEcCtD
Solifenacin—Liver function test abnormal—Doxorubicin—sarcoma	0.00205	0.00267	CcSEcCtD
Solifenacin—Skin disorder—Etoposide—sarcoma	0.00205	0.00267	CcSEcCtD
Solifenacin—Dry skin—Doxorubicin—sarcoma	0.00204	0.00266	CcSEcCtD
Solifenacin—Abdominal pain upper—Doxorubicin—sarcoma	0.00203	0.00265	CcSEcCtD
Solifenacin—Urticaria—Mitoxantrone—sarcoma	0.00201	0.00262	CcSEcCtD
Solifenacin—Abdominal pain—Mitoxantrone—sarcoma	0.002	0.00261	CcSEcCtD
Solifenacin—Muscular weakness—Doxorubicin—sarcoma	0.00196	0.00256	CcSEcCtD
Solifenacin—Dysuria—Epirubicin—sarcoma	0.00194	0.00253	CcSEcCtD
Solifenacin—Dizziness—Thiotepa—sarcoma	0.00194	0.00253	CcSEcCtD
Solifenacin—Influenza—Doxorubicin—sarcoma	0.00192	0.0025	CcSEcCtD
Solifenacin—Hypersensitivity—Vincristine—sarcoma	0.00192	0.0025	CcSEcCtD
Solifenacin—Somnolence—Etoposide—sarcoma	0.00187	0.00244	CcSEcCtD
Solifenacin—Hypersensitivity—Mitoxantrone—sarcoma	0.00187	0.00243	CcSEcCtD
Solifenacin—Asthenia—Vincristine—sarcoma	0.00187	0.00243	CcSEcCtD
Solifenacin—Vomiting—Thiotepa—sarcoma	0.00186	0.00243	CcSEcCtD
Solifenacin—Infestation NOS—Epirubicin—sarcoma	0.00185	0.00241	CcSEcCtD
Solifenacin—Infestation—Epirubicin—sarcoma	0.00185	0.00241	CcSEcCtD
Solifenacin—Vomiting—Dactinomycin—sarcoma	0.00185	0.00241	CcSEcCtD
Solifenacin—Rash—Thiotepa—sarcoma	0.00185	0.00241	CcSEcCtD
Solifenacin—Dermatitis—Thiotepa—sarcoma	0.00185	0.00241	CcSEcCtD
Solifenacin—Headache—Thiotepa—sarcoma	0.00184	0.00239	CcSEcCtD
Solifenacin—Rash—Dactinomycin—sarcoma	0.00183	0.00239	CcSEcCtD
Solifenacin—Decreased appetite—Etoposide—sarcoma	0.00183	0.00239	CcSEcCtD
Solifenacin—Renal failure—Epirubicin—sarcoma	0.00182	0.00237	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Etoposide—sarcoma	0.00182	0.00237	CcSEcCtD
Solifenacin—Asthenia—Mitoxantrone—sarcoma	0.00182	0.00237	CcSEcCtD
Solifenacin—Fatigue—Etoposide—sarcoma	0.00182	0.00237	CcSEcCtD
Solifenacin—Constipation—Etoposide—sarcoma	0.0018	0.00235	CcSEcCtD
Solifenacin—Urinary tract infection—Epirubicin—sarcoma	0.0018	0.00235	CcSEcCtD
Solifenacin—Dysuria—Doxorubicin—sarcoma	0.0018	0.00234	CcSEcCtD
Solifenacin—Hepatobiliary disease—Epirubicin—sarcoma	0.00175	0.00228	CcSEcCtD
Solifenacin—Nausea—Thiotepa—sarcoma	0.00174	0.00227	CcSEcCtD
Solifenacin—Feeling abnormal—Etoposide—sarcoma	0.00174	0.00226	CcSEcCtD
Solifenacin—Nausea—Dactinomycin—sarcoma	0.00173	0.00225	CcSEcCtD
Solifenacin—Gastrointestinal pain—Etoposide—sarcoma	0.00172	0.00224	CcSEcCtD
Solifenacin—Dizziness—Vincristine—sarcoma	0.00172	0.00224	CcSEcCtD
Solifenacin—Infestation NOS—Doxorubicin—sarcoma	0.00171	0.00223	CcSEcCtD
Solifenacin—Infestation—Doxorubicin—sarcoma	0.00171	0.00223	CcSEcCtD
Solifenacin—Renal failure—Doxorubicin—sarcoma	0.00168	0.00219	CcSEcCtD
Solifenacin—Urticaria—Etoposide—sarcoma	0.00167	0.00218	CcSEcCtD
Solifenacin—Abdominal pain—Etoposide—sarcoma	0.00166	0.00217	CcSEcCtD
Solifenacin—Urinary tract infection—Doxorubicin—sarcoma	0.00166	0.00217	CcSEcCtD
Solifenacin—Vomiting—Vincristine—sarcoma	0.00165	0.00215	CcSEcCtD
Solifenacin—Pharyngitis—Epirubicin—sarcoma	0.00165	0.00215	CcSEcCtD
Solifenacin—Urinary tract disorder—Epirubicin—sarcoma	0.00164	0.00214	CcSEcCtD
Solifenacin—Rash—Vincristine—sarcoma	0.00164	0.00214	CcSEcCtD
Solifenacin—Dermatitis—Vincristine—sarcoma	0.00164	0.00213	CcSEcCtD
Solifenacin—Oedema peripheral—Epirubicin—sarcoma	0.00164	0.00213	CcSEcCtD
Solifenacin—Connective tissue disorder—Epirubicin—sarcoma	0.00163	0.00213	CcSEcCtD
Solifenacin—Urethral disorder—Epirubicin—sarcoma	0.00163	0.00212	CcSEcCtD
Solifenacin—Headache—Vincristine—sarcoma	0.00163	0.00212	CcSEcCtD
Solifenacin—Hepatobiliary disease—Doxorubicin—sarcoma	0.00162	0.00211	CcSEcCtD
Solifenacin—Vomiting—Mitoxantrone—sarcoma	0.00161	0.0021	CcSEcCtD
Solifenacin—Rash—Mitoxantrone—sarcoma	0.0016	0.00208	CcSEcCtD
Solifenacin—Dermatitis—Mitoxantrone—sarcoma	0.00159	0.00208	CcSEcCtD
Solifenacin—Headache—Mitoxantrone—sarcoma	0.00159	0.00207	CcSEcCtD
Solifenacin—Erythema multiforme—Epirubicin—sarcoma	0.00157	0.00205	CcSEcCtD
Solifenacin—Eye disorder—Epirubicin—sarcoma	0.00155	0.00202	CcSEcCtD
Solifenacin—Hypersensitivity—Etoposide—sarcoma	0.00155	0.00202	CcSEcCtD
Solifenacin—Nausea—Vincristine—sarcoma	0.00154	0.00201	CcSEcCtD
Solifenacin—Cardiac disorder—Epirubicin—sarcoma	0.00154	0.00201	CcSEcCtD
Solifenacin—Pharyngitis—Doxorubicin—sarcoma	0.00153	0.00199	CcSEcCtD
Solifenacin—Urinary tract disorder—Doxorubicin—sarcoma	0.00152	0.00198	CcSEcCtD
Solifenacin—Oedema peripheral—Doxorubicin—sarcoma	0.00151	0.00197	CcSEcCtD
Solifenacin—Asthenia—Etoposide—sarcoma	0.00151	0.00197	CcSEcCtD
Solifenacin—Connective tissue disorder—Doxorubicin—sarcoma	0.00151	0.00197	CcSEcCtD
Solifenacin—Angiopathy—Epirubicin—sarcoma	0.00151	0.00197	CcSEcCtD
Solifenacin—Urethral disorder—Doxorubicin—sarcoma	0.00151	0.00196	CcSEcCtD
Solifenacin—Nausea—Mitoxantrone—sarcoma	0.0015	0.00196	CcSEcCtD
Solifenacin—Immune system disorder—Epirubicin—sarcoma	0.0015	0.00196	CcSEcCtD
Solifenacin—Mediastinal disorder—Epirubicin—sarcoma	0.0015	0.00195	CcSEcCtD
Solifenacin—Pruritus—Etoposide—sarcoma	0.00149	0.00194	CcSEcCtD
Solifenacin—Mental disorder—Epirubicin—sarcoma	0.00146	0.0019	CcSEcCtD
Solifenacin—Erythema multiforme—Doxorubicin—sarcoma	0.00145	0.00189	CcSEcCtD
Solifenacin—Malnutrition—Epirubicin—sarcoma	0.00145	0.00189	CcSEcCtD
Solifenacin—Eye disorder—Doxorubicin—sarcoma	0.00144	0.00187	CcSEcCtD
Solifenacin—Cardiac disorder—Doxorubicin—sarcoma	0.00143	0.00186	CcSEcCtD
Solifenacin—Dysgeusia—Epirubicin—sarcoma	0.00142	0.00185	CcSEcCtD
Solifenacin—Angiopathy—Doxorubicin—sarcoma	0.00139	0.00182	CcSEcCtD
Solifenacin—Dizziness—Etoposide—sarcoma	0.00139	0.00182	CcSEcCtD
Solifenacin—Immune system disorder—Doxorubicin—sarcoma	0.00139	0.00181	CcSEcCtD
Solifenacin—Mediastinal disorder—Doxorubicin—sarcoma	0.00139	0.00181	CcSEcCtD
Solifenacin—Vision blurred—Epirubicin—sarcoma	0.00136	0.00178	CcSEcCtD
Solifenacin—Mental disorder—Doxorubicin—sarcoma	0.00135	0.00176	CcSEcCtD
Solifenacin—Vomiting—Etoposide—sarcoma	0.00134	0.00175	CcSEcCtD
Solifenacin—Malnutrition—Doxorubicin—sarcoma	0.00134	0.00174	CcSEcCtD
Solifenacin—Rash—Etoposide—sarcoma	0.00133	0.00173	CcSEcCtD
Solifenacin—Dermatitis—Etoposide—sarcoma	0.00133	0.00173	CcSEcCtD
Solifenacin—Headache—Etoposide—sarcoma	0.00132	0.00172	CcSEcCtD
Solifenacin—Dysgeusia—Doxorubicin—sarcoma	0.00131	0.00171	CcSEcCtD
Solifenacin—Palpitations—Epirubicin—sarcoma	0.00128	0.00167	CcSEcCtD
Solifenacin—Cough—Epirubicin—sarcoma	0.00126	0.00165	CcSEcCtD
Solifenacin—Vision blurred—Doxorubicin—sarcoma	0.00126	0.00164	CcSEcCtD
Solifenacin—Nausea—Etoposide—sarcoma	0.00125	0.00163	CcSEcCtD
Solifenacin—Hypertension—Epirubicin—sarcoma	0.00125	0.00163	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00122	0.00159	CcSEcCtD
Solifenacin—Dry mouth—Epirubicin—sarcoma	0.0012	0.00157	CcSEcCtD
Solifenacin—Confusional state—Epirubicin—sarcoma	0.00119	0.00155	CcSEcCtD
Solifenacin—Palpitations—Doxorubicin—sarcoma	0.00118	0.00154	CcSEcCtD
Solifenacin—Anaphylactic shock—Epirubicin—sarcoma	0.00118	0.00154	CcSEcCtD
Solifenacin—Infection—Epirubicin—sarcoma	0.00117	0.00153	CcSEcCtD
Solifenacin—Cough—Doxorubicin—sarcoma	0.00117	0.00152	CcSEcCtD
Solifenacin—Nervous system disorder—Epirubicin—sarcoma	0.00116	0.00151	CcSEcCtD
Solifenacin—Hypertension—Doxorubicin—sarcoma	0.00116	0.00151	CcSEcCtD
Solifenacin—Tachycardia—Epirubicin—sarcoma	0.00115	0.0015	CcSEcCtD
Solifenacin—Skin disorder—Epirubicin—sarcoma	0.00115	0.00149	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00113	0.00148	CcSEcCtD
Solifenacin—Dry mouth—Doxorubicin—sarcoma	0.00111	0.00145	CcSEcCtD
Solifenacin—Confusional state—Doxorubicin—sarcoma	0.0011	0.00144	CcSEcCtD
Solifenacin—Anaphylactic shock—Doxorubicin—sarcoma	0.00109	0.00142	CcSEcCtD
Solifenacin—Infection—Doxorubicin—sarcoma	0.00109	0.00141	CcSEcCtD
Solifenacin—Nervous system disorder—Doxorubicin—sarcoma	0.00107	0.0014	CcSEcCtD
Solifenacin—Tachycardia—Doxorubicin—sarcoma	0.00107	0.00139	CcSEcCtD
Solifenacin—Skin disorder—Doxorubicin—sarcoma	0.00106	0.00138	CcSEcCtD
Solifenacin—Somnolence—Epirubicin—sarcoma	0.00105	0.00137	CcSEcCtD
Solifenacin—Dyspepsia—Epirubicin—sarcoma	0.00104	0.00135	CcSEcCtD
Solifenacin—Decreased appetite—Epirubicin—sarcoma	0.00103	0.00134	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Epirubicin—sarcoma	0.00102	0.00133	CcSEcCtD
Solifenacin—Fatigue—Epirubicin—sarcoma	0.00102	0.00133	CcSEcCtD
Solifenacin—Constipation—Epirubicin—sarcoma	0.00101	0.00132	CcSEcCtD
Solifenacin—Feeling abnormal—Epirubicin—sarcoma	0.000973	0.00127	CcSEcCtD
Solifenacin—Somnolence—Doxorubicin—sarcoma	0.000971	0.00127	CcSEcCtD
Solifenacin—Gastrointestinal pain—Epirubicin—sarcoma	0.000965	0.00126	CcSEcCtD
Solifenacin—Dyspepsia—Doxorubicin—sarcoma	0.000962	0.00125	CcSEcCtD
Solifenacin—Decreased appetite—Doxorubicin—sarcoma	0.00095	0.00124	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000943	0.00123	CcSEcCtD
Solifenacin—Fatigue—Doxorubicin—sarcoma	0.000942	0.00123	CcSEcCtD
Solifenacin—Urticaria—Epirubicin—sarcoma	0.000938	0.00122	CcSEcCtD
Solifenacin—Constipation—Doxorubicin—sarcoma	0.000934	0.00122	CcSEcCtD
Solifenacin—Abdominal pain—Epirubicin—sarcoma	0.000933	0.00122	CcSEcCtD
Solifenacin—Feeling abnormal—Doxorubicin—sarcoma	0.0009	0.00117	CcSEcCtD
Solifenacin—Gastrointestinal pain—Doxorubicin—sarcoma	0.000893	0.00116	CcSEcCtD
Solifenacin—Hypersensitivity—Epirubicin—sarcoma	0.00087	0.00113	CcSEcCtD
Solifenacin—Urticaria—Doxorubicin—sarcoma	0.000868	0.00113	CcSEcCtD
Solifenacin—Abdominal pain—Doxorubicin—sarcoma	0.000864	0.00113	CcSEcCtD
Solifenacin—Asthenia—Epirubicin—sarcoma	0.000847	0.0011	CcSEcCtD
Solifenacin—Pruritus—Epirubicin—sarcoma	0.000835	0.00109	CcSEcCtD
Solifenacin—Hypersensitivity—Doxorubicin—sarcoma	0.000805	0.00105	CcSEcCtD
Solifenacin—Asthenia—Doxorubicin—sarcoma	0.000784	0.00102	CcSEcCtD
Solifenacin—Dizziness—Epirubicin—sarcoma	0.000781	0.00102	CcSEcCtD
Solifenacin—Pruritus—Doxorubicin—sarcoma	0.000773	0.00101	CcSEcCtD
Solifenacin—Vomiting—Epirubicin—sarcoma	0.000751	0.000978	CcSEcCtD
Solifenacin—Rash—Epirubicin—sarcoma	0.000744	0.00097	CcSEcCtD
Solifenacin—Dermatitis—Epirubicin—sarcoma	0.000744	0.000969	CcSEcCtD
Solifenacin—Headache—Epirubicin—sarcoma	0.00074	0.000964	CcSEcCtD
Solifenacin—Dizziness—Doxorubicin—sarcoma	0.000722	0.000942	CcSEcCtD
Solifenacin—Nausea—Epirubicin—sarcoma	0.000701	0.000914	CcSEcCtD
Solifenacin—Vomiting—Doxorubicin—sarcoma	0.000695	0.000905	CcSEcCtD
Solifenacin—Rash—Doxorubicin—sarcoma	0.000689	0.000898	CcSEcCtD
Solifenacin—Dermatitis—Doxorubicin—sarcoma	0.000688	0.000897	CcSEcCtD
Solifenacin—Headache—Doxorubicin—sarcoma	0.000684	0.000892	CcSEcCtD
Solifenacin—Nausea—Doxorubicin—sarcoma	0.000649	0.000846	CcSEcCtD
